- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07856017
Development of an Intraoperative Adaptive Biopsy System for Prostate Cancer: Integrating Imaging Navigation With Metabolic Feedback for Dynamic Decision-Making
An MRI-Based Diagnostic Model for Prostate Cancer Localization: An Exploratory Study Integrating Radiomics and the Metabolic Microenvironment
Development of an Intelligent System Integrating Preoperative Imaging and Real-Time Intraoperative Metabolic Feedback to Dynamically Optimize Biopsy core Placement for Individualized Precision Sampling.
Studieoversigt
Status
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiesteder
-
-
-
Shanghai, Kina
- Rekruttering
- Shanghai Geriatric Medical Center
-
Kontakt:
- Shanghai Geriatric Medical Center
- Telefonnummer: +86 51371990
- E-mail: zsurology@126.com
-
Shanghai, Kina
- Rekruttering
- Zhongshan Hospital, Fudan University
-
Kontakt:
- Zhongshan Hospital, Fudan University
- Telefonnummer: +86 64041990
- E-mail: wang.hang@zs-hospital.sh.cn
-
Shanghai, Kina
- Rekruttering
- Minhang Hospital, Fudan University
-
Kontakt:
- Minhang Hospital, Fudan University
- Telefonnummer: +86 64923400
- E-mail: zsyhuangjq@163.com
-
Shanghai, Kina
- Rekruttering
- Xuhui Hospital, Fudan University
-
Kontakt:
- Xuhui Hospital, Fudan University
- Telefonnummer: +86 36682220
- E-mail: wang.hang@zs-hospital.sh.cn
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Patients who underwent prostate biopsy at three medical centers in Shanghai: Minhang Hospital, Fudan University; Xuhui Hospital, Fudan University and Shanghai Geriatric Medical Center
Beskrivelse
Inclusion Criteria:
- Age ≥55 years;
- Indication for prostate biopsy;
- Availability of total prostate-specific antigen (tPSA), free PSA (fPSA) levels, and multiparametric MRI (mpMRI) results within 1 month prior to biopsy.
Exclusion Criteria:
- Pathological diagnosis of malignancies other than prostatic acinar adenocarcinoma;
- Concomitant malignant tumors potentially affecting imaging findings (e.g., rectal, bladder, or testicular cancer);
- Cachexia or organ function decompensation.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
Adaptive Biopsy Group
Adaptive dynamic biopsy is performed using an intelligent system integrating preoperative imaging data with real-time intraoperative metabolic feedback. |
|
Systemic Biopsy Group
A 10-12-core systematic biopsy. |
|
mpMRI Fusion Targeted Biopsy Group
mpMRI-US fusion-guided targeted prostate biopsy |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Mean number of biopsy cores required to achieve a definitive diagnosis in the adaptive biopsy group
Tidsramme: After 8 weeks of the enrollment process was completed
|
After 8 weeks of the enrollment process was completed
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Prostate cancer detection rate
Tidsramme: After 8 weeks of the enrollment process was completed
|
After 8 weeks of the enrollment process was completed
|
|
Missed diagnosis rates in the adaptive biopsy group and the mpMRI-US fusion-targeted biopsy group
Tidsramme: After 8 weeks of the enrollment process was completed
|
After 8 weeks of the enrollment process was completed
|
|
The time of biopsy
Tidsramme: After 8 weeks of the enrollment process was completed
|
After 8 weeks of the enrollment process was completed
|
|
Complication rate
Tidsramme: After 8 weeks of the enrollment process was completed
|
After 8 weeks of the enrollment process was completed
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Genitale sygdomme
- Patologiske processer
- Genitale neoplasmer, mandlige
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Neoplasmer
- Kønssygdomme, mandlige
- Prostatasygdomme
- Mandlige urogenitale sygdomme
- Neoplasmer efter histologisk type
- Neoplasmer, kirtel og epitel
- Karcinom
- Patologiske tilstande, tegn og symptomer
- Prostatiske neoplasmer
- Sygdom
- Adenocarcinom
Andre undersøgelses-id-numre
- 2026-006-01K
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .